Horizon Therapeutics Public Limited Company

HZNP's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

HZNP Growth rates comparisons

Looking into Horizon Therapeutics Public Limited growth rates, revenue grew by 7.71 % in the second quarter of 2023 from the same quarter a year ago. Ranking at No. 1637

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -8.1 %

Horizon Therapeutics Public Limited's net income grew by 108.4 % in second quarter of 2023 year on year, above company average,

• More on HZNP's Growth

HZNP's Valuation comparisons

Horizon Therapeutics Public Limited
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Company is currently trading with Price to Cash flow multiple of 47.53 in trailing twelve-month period.

Company

62.24

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 7.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

• More on HZNP's Valuation

Total Debt (Millions $)	2,557
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	2,802,652
Net Income/Employee (TTM) $	336,925
Receivable Turnover (TTM)	5.47
Tangible Book Value (Per Share $)	4.29

HZNP's Valuation comparisons

Company

62.24

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 7.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

Horizon Therapeutics Public Limited Price to Book Ratio is at 5.12 lower than Industry Avg. of 39.15. and higher than S&P 500 Avg. of 0.02

• More on HZNP's Valuation

• Market Capitalization (Millions $)	27,190
• Shares Outstanding (Millions)	234
• Employees	1,300
• Revenues (TTM) (Millions $)	3,643
• Net Income (TTM) (Millions $)	438
• Cash Flow (TTM) (Millions $)	572
• Capital Exp. (TTM) (Millions $)	-82
• Total Debt (Millions $)	2,557
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	2,802,652
• Net Income/Employee(TTM) $	336,925
• Receivable Turnover Ratio (TTM)	5.47
• Tangible Book Value (Per Share $)	4.29

• Market Capitalization (Millions $)	27,190
• Shares Outstanding (Millions)	234
• Employees	1,300
• Revenues (TTM) (Millions $)	3,643
• Net Income (TTM) (Millions $)	438
• Cash Flow (TTM) (Millions $)	572
• Capital Exp. (TTM) (Millions $)	-82

HZNP's Profitability Comparisons

Horizon Therapeutics Public Limited achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in second quarter of 2023 to 15.13 % from 4.33 % in I. Quarter.

Horizon Therapeutics Public Limited net profit margin of 13.46 % is currently ranking no. 39 in Major Pharmaceutical Preparations industry, ranking no. 81 in Healthcare sector and number 1101 in S&P 500.

	*Ratio*
• Capital Ratio (MRQ)	4.27
• Total Debt to Equity (MRQ)	0.48
• Tangible Leverage Ratio (MRQ)	3.45
• Asset Turnover Ratio (TTM)	0.4
• Inventory Turnover Ratio (TTM)	5.2

HZNP's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.